key: cord-0800982-5bm5u5hs
authors: Reder, Anthony T.; Centonze, Diego; Naylor, Maria L.; Nagpal, Anjali; Rajbhandari, Rajani; Altincatal, Arman; Kim, Michelle; Berdofe, Aaron; Radhakrishnan, Maha; Jung, Eunice; Sandrock, Alfred W.; Smirnakis, Karen; Popescu, Catrinel; de Moor, Carl
title: COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
date: 2021-03-20
journal: CNS Drugs
DOI: 10.1007/s40263-021-00804-1
sha: 4d3bd583a837b2ddcff38b92e6d7a2033409a1e1
doc_id: 800982
cord_uid: 5bm5u5hs

BACKGROUND: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course. We assessed these risks in patients with MS (PwMS). OBJECTIVE: The objective of this study was to describe the overall risk of coronavirus disease 2019 (COVID-19) infection, severe disease course, and potential population-level predictors of COVID-19 infection in PwMS, and to provide a context using a cohort of patients with systemic lupus erythematosus (SLE). In addition, the association of different MS DMTs with the incidence and clinical course of COVID-19 was evaluated. Safety data from the Biogen Global Safety Database are also presented on reported cases of COVID-19 in patients treated with Biogen MS therapies. METHODS: The IBM(®) Explorys electronic health record database of > 72,000,000 patients from US healthcare networks identified patients with MS or SLE, with and without polymerase chain reaction-confirmed COVID-19. COVID-19 cumulative incidence, hospitalization, and deaths among DMT classes were compared using logistic regression (adjusted for age, sex, body mass index, comorbidities, and race/ethnicity). As a secondary data source to assess safety data, COVID-19 reports for Biogen MS therapies were extracted and described from Biogen’s Global Safety Database. RESULTS: 30,478 PwMS with an open DMT prescription were identified within Explorys; 344 were COVID-19 positive. The most significant risk factors for acquiring COVID-19 were comorbidity score ≥ 1, body mass index ≥ 30, and Black/African ancestry. Similar risk factors were also identified for patients with SLE. Patients with MS were less likely to develop COVID-19 when treated with interferons (0.61%) and glatiramer acetate (0.51%), vs all other MS DMTs (both p < 0.001); anti-CD20 therapy was associated with the highest risk (3.45%; p < 0.0001). In the Biogen Global Safety Database, we identified 1217 patients who were COVID-19 positive treated with intramuscular interferon beta-1a, peginterferon beta-1a, natalizumab, dimethyl fumarate, diroximel fumarate, or fampridine. CONCLUSIONS: Comorbidities, obesity, and Black/African ancestry, but not age, were associated with a higher risk of SARS-CoV-2 infection in PwMS. Interferons and glatiramer acetate were associated with a reduced COVID-19 risk, whereas anti-CD20 therapies were associated with an increased risk, within the treated MS cohort. COVID-19 safety reports for patients receiving Biogen MS therapies were consistent with the Explorys database and MS literature, illustrating the replicability and power of this approach. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40263-021-00804-1.

In the Biogen Global Safety Database, case reports of the clinical course of COVID-19 in patients with MS treated with interferons, natalizumab, fumarates, or fampridine were consistent with the general population. fever, cough, fatigue, dyspnea, myalgia, sputum production, and headache [3, 4] . As of 3 March 2021 there were > 114 million confirmed cases of COVID-19 worldwide and > 22 million confirmed cases in the USA [5] .

Immunocompromised patients infected with SARS-CoV-2, especially those with comorbidities, may have a higher risk for severe outcomes than the general population [6] [7] [8] . Individuals with autoimmune diseases have an increased risk for infections [9, 10] . This increased risk for infections, both community acquired and opportunistic, is associated with intrinsic disease-specific immune dysregulation and/or immune suppression from the use of immune therapies. Immune modification is especially relevant in the context of SARS-CoV-2 infection in persons with autoimmune diseases [11] . Expert guidelines issued for numerous autoimmune diseases in the pandemic have highlighted the potential for an increased risk of infection [12] [13] [14] .

Treatment guidelines for multiple sclerosis (MS), a chronic autoimmune demyelinating disease, take multiple factors into consideration to optimize overall benefit/risk. [15] The COVID-19 pandemic adds to concerns around the overall risk of infection and the potential of an adverse clinical course during management of MS. Preliminary data from registries of patients with MS (PwMS) indicate that the risk of COVID-19 and associated morbidity in the MS population is similar to the general population [7, [16] [17] [18] [19] [20] .

Currently approved MS disease-modifying therapies (DMTs) impact multiple immune mechanisms, including inhibition of immune cell trafficking, immune cell subset depletion, alteration of immune cell function, and inhibition of cell replication [21] . The susceptibility to infection with SARS-CoV-2 and the risk of a severe clinical course of COVID-19 could be impacted by MS treatments as well as MS immune dysregulation and brain pathophysiology [11, [22] [23] [24] . Although risks of infection vary among DMTs, most expert MS guidelines support the continuation of DMTs to prevent further MS disease activity and progression [17-19, 25, 26] , but also encourage discussion of balancing the risks of altering ongoing therapy vs the DMT-associated risk of infection [12] .

Real-world data from comprehensive and large-scale population cohorts such as registries and electronic health record (EHR) databases could help characterize the risk of infection with SARS-CoV-2 in PwMS during the ongoing pandemic. These analyses can define predictors for infection and adverse clinical outcomes. Minority populations, such as those of Black/African ancestry and Hispanic ethnicity, have a higher morbidity and mortality with COVID [27, 28] . Morbidity in these populations is amplified by older age, MS disability, and comorbidities, all associated with a higher risk of acquiring COVID-19 and a more severe clinical course of infection [26, 27, [29] [30] [31] [32] [33] .

We present findings from a retrospective analysis of realworld data in PwMS from the IBM ® Explorys database, a convenience sample of health systems containing EHR data on approximately 72 million unique patients (since 2000) from 39 large health systems in the USA (approximately 400 hospitals and 400,000 providers) [34] . We describe the overall risk of COVID-19 infection, disease course, and potential population-level predictors of COVID-19 infection in PwMS. A cohort with systemic lupus erythematosus (SLE), a chronic autoimmune disease treated with immunemodifying therapy [35] , was used to provide context for the findings in MS [36] . We also report the association of different MS DMTs with the incidence and clinical course of COVID-19. Safety data from the Biogen Global Safety Database (GSD) are also presented on reported cases of COVID-19 in patients treated with Biogen MS therapies, including interferons [IFNs] (Avonex ® and Plegridy ® ), natalizumab (Tysabri ® ), fumarates (Tecfidera ® and Vumerity ® ), and fampridine (Fampyra ® ).

Using the IBM Explorys real-world dataset, PwMS and patients with SLE with an open prescription for a DMT were identified and data evaluated from 1 January 2020 through 30 November 2020 (Fig. 1) . Patients with MS were identified using the standard algorithm of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision codes followed by introducing SNOMED subset codes (Table 4 of the Supplementary Information) . Patients with SLE were similarly identified using SNOMED codes (Table 4 of the Supplementary Information) . Only patients diagnosed with MS or SLE through 1 February 2020 were included, to identify diagnosis-established patients prior to the COVID-19 pandemic. After PwMS or patients with SLE were identified, DMT use was assessed in this subset of patients as follows: an open prescription was defined as a prescription with a defined start date and no end date at the time of diagnosis or hospitalization; this served as a proxy for patients currently being treated with a DMT. Patients for whom the above information was missing in their EHR were categorized as not having an open DMT prescription.

Patients were dichotomized according to whether COVID-19 was or was not confirmed by polymerase chain reaction (PCR). Patients with PCR-confirmed COVID-19 were considered COVID-19 positive; all others were considered COVID-19 negative. Baseline characteristics of PwMS were assessed for potential risk predictors of COVID-19 disease. Comorbidity score was based on comorbidities (hypertension, diabetes mellitus, cardiovascular disease, cancer, chronic obstructive pulmonary disease, chronic kidney disease) recorded in the EHR as the sum of the number of comorbidities for each patient. A score of zero indicated that no comorbidities were found.

Disease-modifying therapies prescribed for MS were categorized by mechanism of action: dihydro-orotate dehydrogenase inhibitor ( 

Biogen utilizes a customized release of ARISg/j (ArisG LifeSphere ® Platform; ArisGlobal, Miami, FL, USA) for its GSD. This drug safety database provides all the functionality required to meet global safety reporting obligations for clinical trial serious adverse events (AEs) and post-marketing AEs. The system allows the collection, coding, assessment, and reporting of clinical and spontaneous AE data in accordance with international guidelines. The system enables the capture of AEs reported to Biogen from healthcare providers, consumers, or other sources, as well as those reported in the literature. The results described here are based on data collected from the date of the first marketing authorization for a given Biogen product through 3 December 2020. Safety data reported here include AEs reported to Biogen that contained COVID-19-related Preferred Terms from COVID-19 Standard MedDRA query (details presented in Table 3 of the Supplementary Information) between 1 January through 3 December 2020. Outcomes for these cases were classified for seriousness, as defined by standard International Conference on Harmonisation definitions and instances of fatal outcome [37] . Reporting rates for each product were calculated using the total number of COVID-19 cases divided by the cumulative exposure.

We assessed descriptive summaries and differences in proportions of disease characteristics and DMTs. P values were calculated based on the Chi-square or Fisher's exact test. Comparisons of cumulative incidence of COVID-19 between DMTs were made using logistic regression adjusted for patient age, sex, body mass index (BMI), comorbidities, and race. Multivariate logistic regression analyses utilized penalized maximum likelihood estimation (Firth's bias correction) to mitigate data separation issues owing to the small sample size. Adjusted odds ratio (OR) estimates and 95% confidence intervals (CIs) based on penalized profile likelihood estimates are presented. Differences in proportions for DMT use by mechanism of action were calculated using fumarates as the reference product. The fumarate class was selected as the reference product because of its widespread use globally and the neutral effect on the risk of developing COVID-19 reported in other datasets in the MS patient population [33, 38] .

Descriptive analysis of reports of COVID-19 in PwMS receiving Biogen therapies within the Biogen GSD include serious and non-serious events including fatal outcomes and cumulative reporting rate (95% CI) per 1000 patient-years.

In the IBM Explorys database, 153,663 patients had a diagnosis of MS. Of the PwMS, 30,478 had a recorded open prescription for a DMT. The incidence of COVID-19 was 0.50% (n = 761) for the overall MS population and 1.13% (n = 344) in patients receiving DMTs. COVID-19 incidence was ~ 0.4% in PwMS with no open DMT prescription, a population enriched for no treatment, yet likely containing some receiving treatment because of incomplete EHR documentation or current inactivity in the EHR system. This limitation precludes any definitive comparison between patients receiving and not receiving DMTs.

In the Explorys database, PwMS were primarily female (74%), white (75%), and non-Hispanic (68%). There were 17,661 (11%) patients identified as having Black/African ancestry and 4789 (3%) identified as Hispanic; the others were of unknown race or ethnicity. Patients with MS were primarily 40-49 (20%), 50-59 (21%), and 60-69 (27%) years of age. BMI was ≥ 30 kg/m 2 in 29% of PwMS. Fiftyfour percent of PwMS had a comorbidity score ≥ 1. Of the individual comorbidities, 43% were diagnosed with hypertension, 18% with diabetes, 15% with cardiovascular disease, 19% with cancer, 12% with chronic obstructive pulmonary disease, and 6% with chronic kidney disease.

Patients with MS at a higher risk of contracting COVID-19 included those with a comorbidity score ≥ 1, with higher BMI (≥ 30 kg/m 2 ), and who had Black/African ancestry (Table 1) . Patients with comorbidities such as hypertension, diabetes, chronic obstructive pulmonary disease, and chronic kidney disease were at a higher risk of contracting COVID-19 (Table 1) .

Patients with MS with an open prescription of an MS DMT in the Explorys database were primarily female (75%), white (78%), and non-Hispanic (75%). In total, there were 3780 (12%) patients who identified as having Black/African ancestry and 836 (3%) who identified as Hispanic; the others were of unknown race or ethnicity. Patients with MS receiving DMT were primarily 40-49 (24%), 50-59 (25%), and 60-69 (27%) years of age. BMI was ≥ 30 kg/m 2 in 36% of PwMS. Fifty-two percent of PwMS receiving DMT had a comorbidity score ≥ 1; 40% were diagnosed with hypertension, 15% with diabetes, 11% with cardiovascular disease, 14% with cancer, 8% with chronic obstructive pulmonary disease, and 5% with chronic kidney disease. The crude risk of developing COVID-19 with different MS DMTs (categorized by proposed mechanism of action) was as follows: anti-CD20, 3.45%; anti-VLA-4, 1.35%; S1P modulators, 1.07%; fumarates, 1.01%; dihydro-orotate dehydrogenase inhibitors, 0.90%; IFNs, 0.61%; and GA, 0.51% ( Table 2) .

The odds of developing COVID-19 relative to fumarates were higher for anti-CD20 therapies (OR, 3.25 [95% CI 2.31-4.64]; p < 0.0001) (Fig. 2) . Anti-CD20 therapies also had a higher risk of developing COVID-19 when compared with anti-VLA-4 antibodies (OR, 2.32 [95% CI 1.56-3.57]; p < 0.0001) and IFNs (OR, 4.65 [95% CI 3.23-6.82]; p < 0.0001). The odds of developing COVID-19 were lower in patients treated with GA compared with fumarates (p = 0.006) and to anti-VLA-4 antibodies (p < 0.002). There was no difference in risk with GA compared to IFNs. The odds of COVID-19 infection relative to IFNs was higher in patients receiving anti-VLA-4 antibodies (OR, 2.00 [95% CI 1.21-3.27]; p = 0.005) and S1P modulators (OR, 1.65 [95% CI 1.01-2.68]; p = 0.041). However, the difference in risk was not significant when fumarates were compared to anti-VLA-4 antibodies (p = 0.159) or S1P modulators (p = 0.543).

Compared 

The risk of hospitalization due to COVID-19 in PwMS with an open DMT prescription was 21.5% (n = 74/344). Deaths due to COVID-19 was 4.2% (n = 32/761) in the overall MS population and 3.5% (n = 12/344) in PwMS with an open DMT prescription (Fig. 3 (Table 3) . Patients with a higher comorbidity score (≥ 1) had a higher risk of hospitalization due to COVID-19, and an increasing comorbidity score was associated with an increased risk of hospitalization due to COVID-19 ( Table 3 ). The risk of COVID-19-related hospitalization by DMT use (Table 4 ) was similar to risk of COVID-19 incidence ( Table 2 ). The number of deaths from COVID-19 was small in PwMS treated with DMTs (n = 12) and in the overall MS population (n = 32). However, a higher comorbidity score and older age may be associated with an increased risk (data not shown). (Fig. 3 ) and for patients with SLE in the overall database population (3.8%; n = 39/1021; data not shown). However, chronic kidney disease, hypertension, diabetes, and older age may be associated with increased risk (data not shown).

The Biogen GSD contains data on five MS DMTs belonging to different drug classes, including fumarates (dimethyl fumarate, diroximel fumarate), anti-VLA-4 antibodies (natalizumab), and IFNs (intramuscular IFNβ-1a, pegIFNβ-1a), as well as a symptomatic therapy (fampridine). As of 3 December 2020, 1.59 million patients have been treated with one of these therapies. This is the most comprehensive global safety database on MS therapies in the industry and provides a unique opportunity to review the impact of COVID-19 on patients treated with DMTs. Between 1 January and 3 December 2020, Biogen received 1217 case reports of COVID-19 in patients treated with a product in the Biogen MS portfolio ( 

Emerging registry and survey data indicate that the MS population may not have an increased risk of COVID-19 [17, 18, 30, 31, 39] . However, MS-associated disability and DMT therapy have been reported to be independent predictors of a higher risk of COVID-19 infection [26, 32] . Variation in COVID-19 risk may be due to differences in MS patient populations, such as progressive disease, older patients, and severe disability, where an effective DMT may be unavailable. Recent guidelines argue that continuing DMT therapy can prevent disease progression and discuss the benefit vs risk of ongoing DMT therapy in the context of local COVID-19 infections [12] . Epidemiological data reveal disparities in COVID-19 prevalence and disease outcomes among different racial and ethnic subgroups [27, [29] [30] [31] [32] . In the USA, the rate of COVID-19 cases and COVID-19-associated mortality in patients with Black/African ancestry and Hispanic patients is disproportionately higher than their representation in the overall population [27] . Patients with MS with Black/African ancestry in this cohort, though limited in number, had a higher incidence of COVID-19 than PwMS with no Black/ African ancestry [27, 28] . Similar trends were observed for hospitalization due to COVID-19. COVID-19 incidence trended higher in a similar manner for Hispanic patients. However, demographic data in the Explorys database were incomplete in many cases. Data sets and registries that focus on engagement with minority populations and that capture comprehensive race and ethnicity-based data in the context of COVID-19 incidence, outcomes, and access to healthcare and vaccination are needed.

The incidence of developing COVID-19 in PwMS with an open DMT prescription (1.13%) is equivalent to incidence in patients with SLE with an open DMT prescription (1.19%). The varied immune effects and mechanisms of action of MS DMTs likely cause variation in the general risk of infection, consequent disease severity, and virus-induced MS reactivation/inflammation [23, 33, 40] . Real-world COVID-19 registries such as MuSC-19, COVISEP, and the MS Global Data Sharing Alliance indicate that IFNs and GA are associated with a reduced risk of developing COVID-19 (relative to other DMTs), while anti-CD20 therapies are associated with an increased risk for COVID-19 [12, 16, 23, 33, 41, 42] . Our analysis shows similar trends in the risk of COVID-19.

The risk of infection with different DMT classes was studied in relation to fumarates, given that fumarates have been identified in prior studies as one of the most prescribed class of DMT for PwMS [33, 43] . Previous analyses showed a neutral impact of fumarates on the COVID-19 infection rate and are consistent with the data reported in this study [33, 38] . The incidence of COVID-19 in patients treated with fumarates was 1.01%, and the overall MS population with an open DMT prescription was similar at 1.13%. While fumarates may decrease lymphocyte counts [44, 45] , patients treated with fumarates have functional T and B cells [46] , have stable serum IgA, IgG, IgM, and IgG1-4 over 2 years of treatment, and have adequate seroprotective responses to inactivated vaccines [47] . These and other analyses suggest no impairment of function despite a decrease in absolute lymphocyte count [48] . When stratified by absolute lymphocyte count, there is no increase in infection, with the exception of PML [44] . In addition to the effect of fumarate treatment on immune cells, S1P receptor modulator treatment may reduce lymphocyte counts [49] and anti-CD20 treatment is associated with an increased risk of hypogammaglobulinemia [50] . While the effects listed above are important and relevant in the context of COVID-19, this current study was not designed to directly assess the biological effects of the MS DMTs. In our current readout, when compared to fumarates, the increased risk of COVID-19 infection with anti-CD20 therapies remained consistent and statistically significant relative to IFNs and to anti-VLA-4 antibodies.

It is expected that IFNs may affect the COVID-19 risk, given that IFNs are antiviral agents [24, 33, 51] . Recent reports of severe cases of COVID-19 among patients with mutations in type I IFN immunity [52] , low expression of the IFN receptor gene IFNAR2 [53] , and the presence of anti-IFN neutralizing antibodies [54] suggest that type I IFNs are likely to enhance protective immunity against SARS-CoV-2. However, available clinical trial data suggest that IFNs (used alone or in combination with antiviral agents) have mixed results in patients with SARS-CoV-2 in alleviating symptoms and shortening the duration of both viral shedding and hospital stays [55] [56] [57] [58] [59] . Although the lower risk of infection observed with GA could be associated with indirect effects on the immune system, the impact of GA-induced immune alterations is still undefined [55] [56] [57] [58] . It remains to be determined whether the reduced risk during IFN and GA therapy is driven by modification of immunity or is from differences in patient and disease characteristics (i.e., these DMTs are prescribed for patients who are earlier in disease evolution, have milder disease activity, or less disability).

The risk of COVID-19-related hospitalization by DMT use (Table 4 ) was similar to the trends observed in the MuSC-19 study and MS Global Data Sharing Alliance databases [33, 38] . Given the overall low reports of hospitalization and deaths in our dataset, it is not possible to draw strong conclusions about the effect of different DMT classes on these outcomes. Multiple sclerosis-associated disability has been reported as an independent predictor of a higher risk of infection. Patients with MS who are not receiving DMT treatment may have a greater risk of infection and severe disease course of COVID-19 than those receiving therapy [26, 32] . This may potentially be associated with inherent differences in patient populations, for example, untreated PwMS may be individuals with progressive disease, older patients, or those with a severe disability, where an effective DMT option may be unavailable. Simpson-Yap et al. and Sormani et al. reported that patients receiving anti-CD20 therapies have an increased severity of COVID-19, with more hospitalizations (intensive care unit admission and/or need for ventilation) relative to other DMTs such as dimethyl fumarate and natalizumab [33, 38] . Anti-CD20 therapies impact the humoral immune response, decrease levels of IgG and IgM over time, attenuate response to inactivated vaccines, and may have additional immunoregulatory effects that modify responses to COVID-19 [59] [60] [61] .

The SARS-CoV-2 pandemic changed patient care and DMT use in MS [62] . In some cases, treatment protocols were adjusted to postpone or discontinue the administration of some DMTs. Recent updates to US and international MS guidelines underscore the importance of continuing DMT treatment and evaluating the risk of infection with different DMTs [12, 63, 64] .

The Biogen GSD represents a useful platform for analyzing reported COVID-19-related events in 1.59 million patients treated across the portfolio of six Biogen MS therapies. COVID-19 cases and deaths in treated patients within the GSD are similar to observations in registry and survey datasets [18, 30, 38, 39, 65] . All cases had clinical courses consistent with COVID-19 as described in the general population. However, pharmacovigilance data are subject to multiple limitations. Because these data are spontaneously reported, details of patient characteristics, comorbidities, disease course, and outcomes are often limited and inconsistently supplied by healthcare providers. Limitations are accentuated by the high medical workload during the COVID-19 pandemic. Finally, selection bias may lead to under-reporting of mild cases, but more accurate reporting of moderate-to-severe cases. Therefore, the true incidence and/or severity of COVID-19 infection, or positive tests, cannot be known from these data. For this reason, we have not made conclusions regarding the comparative reporting rates of COVID-19 in this dataset. Nonetheless, there is currently no evidence to suggest an increased risk of COVID-19 infection in patients treated with these MS therapies.

For the IBM Explorys results, conclusions are limited by the low number of patients with COVID-19 in the MS cohort (n = 344), the lack of a healthy population comparator cohort, the retrospective nature of the study, and the large proportion of PwMS without an open DMT prescription (n = 123,185), potentially owing to incomplete data capture within the EHR database. Given that only ~ 20% of patients in the database had an open DMT prescription, it is likely that the "no open prescription" status reflects an incomplete data capture within this database. There also may have been patients in the database who were treated with an MS DMT without documentation in the EHR. Separately, decisions to treat with a DMT may be based on a perceived benefit-risk profile, leading to potential selection bias in those patients with an open DMT prescription. Thus, the resulting sample population may not be optimally representative of the prevalent MS population in the USA. Given the limited availability of COVID-19 testing in the first half of the data collection period, under-reporting of mild cases is likely during that timeframe. Asymptomatic COVID-19 cases are also likely to be missed in the IBM Explorys database or the Biogen GSD, resulting in potential misclassification bias. For example, if the frequency of developing symptoms of COVID-19 is lower with IFNs or GA than with anti-CD20 treatment, patients treated with IFNs or GA will more often be under-reported. While we acknowledge this analysis evaluated real-world data on patients receiving MS DMTs from two diverse databases, IBM Explorys and Biogen's GSD, it is relevant to note that a profile emerges from the Biogen GSD regarding COVID-19 infection rates and clinical course in patients receiving IFNs, fumarates and natalizumab, which is consistent with both the real-world data from Explorys and with prior reports from other registry datasets. [18, 30, 38, 39, 65] .

Disease-modifying therapies have different biological mechanisms, potentially explaining the differential risk and course of COVID-19 with different DMTs. Disease state (e.g., relapsing or progressive form of MS), disease severity, age, and level of disability may also contribute to variance in the rate of infection. Because EDSS data are absent from the EHR dataset, the impact of EDSS on the risk of infection is not evaluated. Furthermore, rates of infections follow risk behavior, including social distancing, mask wearing, occupation, and ventilation, as well as the COVID-19 prevalence in the local community.

With the availability of vaccines against SARS-CoV-2, the benefit vs risk for individual DMTs will be revisited. Antibody response to vaccines is reduced with anti-CD20s, alemtuzumab, and S1Ps [25] . However, there are adequate antibody responses to vaccines with anti-VLA-4 antibodies, IFNs, fumarates, and GA [25] . There is likely a mechanistic interaction between vaccine responses, MS immune disruption, and immune alterations from DMTs [25, 66] . Effects of DMTs on vaccine responses have implications for optimization of therapy and for public health, in MS and other chronic immune-mediated diseases.

Analyses of the IBM Explorys dataset and Biogen GSD expand and confirm findings from other real-world registries, and demonstrate that PwMS do not have a higher risk of infection with SARS-CoV-2. Comorbidities elevate the frequency of infection. Disease-modifying therapies also modify the risk of infection, likely dependent on their mechanisms of action. Patients with MS taking IFNs and GA had the lowest risk of COVID-19, and patients receiving anti-CD20 therapies had the highest risk. Despite the limitations of the data sources, these findings enhance strategic and personalized approaches to managing DMTs in MS during the ongoing COVID-19 pandemic.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s40263-021-00804-1.

Ethics approval Not applicable.

The data extracted from the databases were entirely anonymized and therefore do not require informed consent.

Availability of data and material The datasets generated during and/ or analyzed during the current study are not publicly available because Biogen does not own the data and it would be difficult to make this data source public, but the portions that are publicly available will be provided by the corresponding author on reasonable request.

Author contributions All authors have read and approved the final manuscript. ATR provided writing, data analysis, and the scientific basis of the text. DC provided discussion on methods of the study and critical reading of the manuscript. MLN and AN provided the scientific basis of the text, data analysis and interpretation, and writing. RR and AA provided data analysis and interpretation. MK and AB provided data management and informatics support. MR provided the scientific basis of the text and interpretation. EJ provided electronic health record subject matter expert guidance, and data management and informatics support. AWS provided the scientific basis of the text and interpretation. KS and CP provided expert information from the Biogen Global Safety Database. CdM provided data analysis and interpretation.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by-nc/4. 0/.

World Health Organization. Pneumonia of unknown cause: China

COVID-19: navigating the uncharted

The epidemiology and clinical information about COVID-19

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2020. https:// covid 19. who. int/? gclid= EAIaI QobCh MIz-i4-f2i7A IVjIF aBR0Z XAxOE AAYAS AAEgI iDPD_ BwE

SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity

Multiple sclerosis disease-modifying therapies in the COVID-19 era

COVID-19 global rheumatology alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Infections in patients with multiple sclerosis: a national cohort study in Sweden

Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies

COVID-19 immunopathology and the central nervous system: implication for multiple sclerosis and other autoimmune diseases with associated demyelination

MS International Federation. Global COVID-19 advice for people with MS. 2020

Consensus statement on immune modulation in multiple sclerosis and related disorders during the COVID-19 pandemic: expert group on behalf of the Indian Academy of Neurology

Centers for Disease Control and Prevention. If you are immunocompromised, protect yourself from COVID-19. 2020

Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Bar-Or A. COVID-19 and MS disease-modifying therapies

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center

Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus

SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients

Infections in patients with multiple sclerosis: implications for disease-modifying therapy

Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis

The COVID-19 pandemic and the use of MS diseasemodifying therapies

Type 1 interferons as a potential treatment against COVID-19

Effects of MS disease-modifying therapies on responses to vaccinations: a review

Covisep Investigators. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis

COVID-19 disparity among racial and ethnic minorities in the US: a cross sectional analysis

Variation in racial/ethnic disparities in COVID-19 mortality by age in the United States: a cross-sectional study

COVID-19 in MS patients: susceptibility and severity risk factors

COVID-19 infection in patients with multiple sclerosis: an observational study by The New York

COVID-19: Considerations for DMTs in MS Neuro-Immunology Consortium (NYCNIC)

COVID-19 in multiple sclerosis: the Dutch experience

COVID-19 in multiple sclerosis patients and risk factors for severe infection

Musc-19 Study Group. Disease modifying therapies and COVID-19 severity in multiple sclerosis

IBM. Explorys EHR solutions

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach

Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: guideline for good clinical practice

First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 outcomes. MSVirtual2020; ECTRIMS/ ACTRIMS

Incidence and clinical outcome of COVID-19 in a cohort of 11.560 Brazilian patients with multiple sclerosis. MSVirtual2020; ECTRIMS/ACTRIMS

Disease-modifying therapies and infectious risks in multiple sclerosis

Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

Associations of DMT therapies with COVID-19 severity in multiple sclerosis

Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations

Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

Immune response to vaccines is maintained in patients treated with dimethyl fumarate

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

Use and safety of interferon beta-1b during the COVID-19 outbreak: current data from a pharmacovigilance safety database

Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19

Genetic mechanisms of critical illness in COVID-19

Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

The evolving mechanisms of action of glatiramer acetate

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis

Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS

Immunological aspects of approved MS therapeutics

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study

Effect of rituximab on human in vivo antibody immune responses

Ocrevus highlights of prescribing information

Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices

National Multiple Sclerosis Society. MS treatment guidelines during the coronavirus pandemic

COVID-19 in persons with multiple sclerosis treated with ocrelizumab -a pharmacovigilance case series

COVID-19 and multiple sclerosis: predisposition and precautions in treatment

Acknowledgements Biogen provided funding for medical writing support in the development of this manuscript; Karen Spach, PhD, from Excel Scientific Solutions wrote sections of the first draft of the manuscript based on extensive input from authors, and Nathaniel Hoover from Excel Scientific Solutions copy edited and styled the manuscript as per journal requirements. The authors gratefully acknowledge the contribution of Bernd Kieseier during the early stages of this work. The authors reviewed and revised the manuscript and had full editorial control of the manuscript and provided their final approval of all content.